In a filing, Aldeyra Therapeutics Inc revealed its Principal Financial Officer Alfieri Michael acquired Company’s shares for reported $13250.0 on Aug 13 ’25. In the deal valued at $5.30 per share,2,500 shares were bought. As a result of this transaction, Alfieri Michael now holds 2,500 shares worth roughly $13475.0.
Then, Machatha Stephen sold 22,073 shares, generating $113,713 in total proceeds. Upon selling the shares at $5.15, the Chief Development Officer now owns 221,799 shares.
Before that, Machatha Stephen bought 22,074 shares. Aldeyra Therapeutics Inc shares valued at $116,109 were divested by the Officer at a price of $5.26 per share.
Oppenheimer upgraded its Aldeyra Therapeutics Inc [ALDX] rating to an Outperform from a a Perform in a research note published recently. H.C. Wainwright started covering the stock on February 08, 2021. It rated ALDX as “a Buy”.
Price Performance Review of ALDX
On Friday, Aldeyra Therapeutics Inc [NASDAQ:ALDX] saw its stock jump 1.70% to $5.39. Over the last five days, the stock has gained 2.47%. Aldeyra Therapeutics Inc shares have risen nearly 14.44% since the year began. Nevertheless, the stocks have risen 8.02% over the past one year. While a 52-week high of $7.20 was reached on 03/12/25, a 52-week low of $1.14 was recorded on 04/03/25.
Levels Of Support And Resistance For ALDX Stock
The 24-hour chart illustrates a support level at 5.29, which if violated will result in even more drops to 5.20. On the upside, there is a resistance level at 5.44. A further resistance level may holdings at 5.50.
How much short interest is there in Aldeyra Therapeutics Inc?
A steep rise in short interest was recorded in Aldeyra Therapeutics Inc stocks on 2025-07-31, growing by 0.57 million shares to a total of 5.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 4.47 million shares. There was a rise of 11.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 16, 2020 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
